$7m market cap

$1.25 last close

OpGen is a diagnostic company focused on revolutionizing the identification and treatment of bacterial infections. The Acuitas AMR Gene Panel molecular test, in combination with the Acuitas Lighthouse bioinformatics product, detects multiple pathogens and predicts antibiotic resistance in less than three hours.

Investment summary

OpGen is a diagnostic company focused on revolutionising the identification and treatment of bacterial infections. Its system allows for the detection of five pathogens and 47 resistance genes and mutations, while predicting the resistance for 14 antibiotics in less than three hours, a major improvement over the two to three days current methods require. It recently announced a plan to merge with Curetis, a Germany-based molecular diagnostics company with a similar focus on infectious disease. Closure of the merger, which is subject to shareholder votes, is expected in Q120.

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 3.2 (15.3) (15.6) (19624.85) N/A N/A
2018A 2.9 (13.2) (13.4) (3351.27) N/A N/A
2019E 3.5 (12.3) (12.6) (642.50) N/A N/A
2020E 5.3 (15.7) (15.8) (281.16) N/A N/A
Industry outlook

It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.

Last updated on 03/12/2019
Share price graph
Balance sheet
Forecast net cash (US$m) 5.2
Forecast gearing ratio (%) N/A
Price performance
Actual (85.7) (81.0) (96.0)
Relative* (86.3) (82.6) (96.5)
52-week high/low US$2.2/US$0.2
*% relative to local index
Key management
Evan Jones CEO
Tim Dec CFO